Nuestro grupo organiza más de 3000 Series de conferencias Eventos cada año en EE. UU., Europa y América. Asia con el apoyo de 1.000 sociedades científicas más y publica más de 700 Acceso abierto Revistas que contienen más de 50.000 personalidades eminentes, científicos de renombre como miembros del consejo editorial.
Revistas de acceso abierto que ganan más lectores y citas
700 revistas y 15 000 000 de lectores Cada revista obtiene más de 25 000 lectores
Megan Smith, Chris Mehdizadeh, Avrodet Mourkus, Saad Ansari A
Cefepime is a broad-spectrum fourth-generation cephalosporin with activity against both gram positive and negative bacteria, including Pseudomonas aeruginosa [1]. Cefepime is most commonly used for urinary tract infections, soft tissue infections, and febrile neutropenia [2]. Up to 15% of ICU patients on cefepime may experience cefepime-induced neurotoxicity, with risk factors including renal dysfunction, excessive dosage, elevated serum cefepime concentrations, and history of prior brain injury [3].
The adverse effects of cefepime-induced neurotoxicity including encephalopathy, seizures, and coma can be resolved with drug cessation, antiepileptics, or hemodialysis [3]. Here, we present the case of cefepime induced neurotoxicity in a 59-year-old female patient with long-term cefepime antibiotic prescription for Pseudomonal endocarditis and bacteremia with multiple risk factors for reduced renal function. We discuss the relevant risk factors and preventive measures that may have prevented her from developing encephalopathy, as well as the importance of early recognition and prevention of cefepime-induced neurotoxicity in patient care.